Immunome (NASDAQ:IMNM) is a pioneer in the field of antibody discovery and immune system targeting for the treatment of cancer and infectious diseases. Utilizing their proprietary Discovery Engine, the company aims to identify novel therapeutic antibodies through the analysis of the human immune response. Their projects are focused on developing solutions that harness the power of the immune system to fight disease more effectively. Objectives include advancing their pipeline of antibody-based therapies through clinical trials to address unmet medical needs, particularly in areas where current treatments fall short. With innovation at its core, Immunome is committed to improving patient outcomes through groundbreaking research and development.